Surface plasmon resonance sensor for heparin measurements in blood plasma

Biosensors and Bioelectronics

Volumn 13, Issue 12, 1998, Pages 1307-1315

  Gaus, Katharina ^a   Hall, Elizabeth A H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Anticoagulant; Polyethylene imine (PEI); Protamine

Indexed keywords

ADSORPTION; BLOOD; DRUG PRODUCTS; POLYIMIDES; POLYSACCHARIDES; RESONANCE;

HEPARIN; POLYETHYLENE IMIDE; PROTAMINE; SURFACE PLASMON RESONANCE (SPR);

BIOSENSORS;

HEPARIN;

ADSORPTION; ARTICLE; BIOSENSOR; DIAGNOSTIC ACCURACY; HUMAN; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SURFACE PLASMON RESONANCE;

BIOSENSING TECHNIQUES; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME; PROTAMINES; SURFACE PLASMON RESONANCE;

EID: 0032409521     PISSN: 09565663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0956-5663(98)00094-3     Document Type: Article

References (37)

1. Barnett H.G., Clifford J.R., Llewellyn R.C. Safety of mini dose heparin administration for neurosurgical patients. Journal of Neurosurgery. 47:1977;27-34.
2. Barrowcliffe, T.W., 1989. Heparin, assays and standardization. In: Lane, D.A., Lindahl, U. (Eds.). Edward Arnold, London, pp. 393-417.
3. Barrowcliffe T.W., Johnson E.A., Thomas D. Antithrombin III and heparin. British Medical Bulletin. 34:1978;143-145.
4. Björk I., Lindahl U. Mechanism of the anticoagulant action of heparin. Molecular and Cellular Biochemistry. 48:1982;161-169.
5. Bjornsson T.D., Wolfram K.M. Intersubject variability in the anticoagulant response to heparin in vitro. European Journal of Clinical Pharmacology. 21:1982;491-497.
6. Bounameaux H., Marbet G.A., Lämmle B., Eichlsberger R., Duckert F. Monitoring of heparin treatment: comparison of thrombin time, activated partial thromboplastin time, and heparin concentration, and analysis of the behavior of antithrombin III. American Journal of Clinical Pathology. 74:1980;68-73.
7. Casu, B. (1989) Methods of Structural analysis. In: Heparin, chemical and biological properties, clinical applications. Lane, D.A., Lindahl, U. (Eds.). Edward Arnold, London, pp. 25-51.
8. Damus P.S., Hicks M.S., Rosenberg R.D. Anticoagulant action of heparin. Nature. 246:1973;355-362.
9. Dawes J., Pepper D.S. A sensitive competitive binding assay for exogenous and endogenous heparin. Thrombosis Research. 27:1982;287-296.
10. Gaus K., Hall E.A.H. Evaluation of surface plasmon resonance (SPR) for heparin assay. Part II: Polyethylene imine (PEI) as an affinity surface. Journal of Colloid and Interface Science. 194:1997;373-378.
11. Gaus K., Hall E.A.H. Evaluation of surface plasmon resoncance (SPR) for a heparin assay. Part I: Protamine as a heparin affinity surface. Journal of Colloid and Interface Science. 194:1997;364-372.
12. Gitel S.N., Medina V.M., Wessler S. Antiheparin antibodies: their preparation and use in a heparin immunoassay. Journal of Laboratory and Clinical Medicine. 109:1987;672-678.
13. Grossman, W., 1986. Complications of cardiac catheterization: incidence, causes and prevention. In: Cardiac catheterization and angiography. Grossman, W. (Eds.). Lea and Febiger, Philadelphia.
14. Hirsh J. Heparin. New England Journal of Medicine. 324:1991;683-689.
15. Holm H.A., Kalvenes S., Abildgaard U. Changes in plasma anithrombin (heparin cofactor activity) during intravenous heparin treatment: observations in 198 patient with deep venous thrombosis. Scandinavian Journal of Haemostasis. 35:1985;564-569.
16. Holm M.A., Abildgaard U., Larsen M.l., Kalvenes S. Monitoring heparin therapy: should heparin assays also reflect the patient's antithrombin concentration? Thrombosis Research. 46:1987;669-675.
17. Jaques L.B., Wice S.M., Hiebert L.M. Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities. Journal of Laboratory and Clinical Medicine. 115:1990;422-432.
18. Jordan R.E., Oosta G.M., Gardner W.T., Rosenberg R.D. The kintics of haemostatic enzyme-antithrombin interaction in the presence of low molecular weight heparin. Journal of Biological Chemistry. 255:1980;400-408.
19. Kakkar, V.V., Hedges, A.R., 1989. Use of heparin as a prophylactic agent against venous thromboembolism. In: Heparin, chemical and biological properties, clinical application. Lane, D.A., Lindahl, U. (Eds.). Edward Arnold, London.
20. Kakkar V.V., Corrigan T., Spindler J. Efficiency of low doses of heparin in prevention of deep vein thrombosis after major surgery. A double-blind randomized trial. Lancet. ii:1972;101-109.
21. Kessler M., Hall E.A.H. Kinetics of silver tarnishing by NOx: a time-dependent surface plasmon resonance study. Journal of Colloid and Interface Science. 169:1995;422-427.
22. Klein M.D., Drongowski R.A., Linhardt R.J., Langer R.S. A colorimetric assay for chemical heparin in plasma. Analytical Biochemistry. 124:1982;59-64.
23. Levy S.W., Jaques L.B. Appearance of heparin anti-thrombin-active chains in vivo after injection of commercial heparin in anaphylaxis. Thrombosis Research. 13:1978;429-441.
24. Linhardt R.J. Heparin: an important drug enters its seventh decade. Chemistry Industry. 21:1991;45-50.
25. Ma S.-C., Yang V., Fu B., Meyerhoff M. Electrochemical sensor for heparin: further characterisation and bioanalytical applications. Analytical Chemistry. 65:1993;2078-2084.
26. Nieduszynski, I., 1989. General physical properties of heparin. In: Heparin, chemical and biological properties, clinical applications. Lane, D.A., Lindahl, U. (Eds.). Edward Arnold, London, pp. 51-65.
27. Rosenberg, R.D., 1982. The heparin-antithrombii system: a natural anticoagulant mechanism. In: Haemostasis and thrombosis. Colman, R.W., Hirsh, J., Marder, V.J., Salzman, E.W. (Eds.). J.B. Lippincott, Philadelphia.
28. Steffenson K.A. Coronary occlusion treated with small doses of heparin. Acta Medica Scandinavica. 186:1969;519-524.
29. Teien N.A., Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding puified antithrombin III. Thrombosis Research. 10:1977;399-407.
30. Thomas D.P., Curtis A.D., Barrowcliffe T.W. A collaborative study designed to establish the 4th International Standard for heparin. Thrombosis Haemostasis. 52:1984;148-153.
31. Van Kerkhof J.C., Bergveld P., Schasfoort R. Development of an ISFET based heparin sensor using the ion-step measuring method. Biosensors and Bioelectronics. 8:1993;463-472.
32. Kerkhof J.C., Bergveld P., Schasfoort R. The ISFET based heparin sensor with a monolayer of protamine as affinity ligand. Biosensors and Bioelectronics. 10:1995;269-282.
33. Van Putten J., Van de Ruit M., Beunis M., Hemker H.C. Interindividual variation in relationships between plasma heparin concentration and the result of five heparin assays. Clinica Chimica Acta. 122:1982;261-270.
34. Vinazzer H. Zur Bestimmung von Heparin in Plasma. Qualitätsvergleich verschiedener Methoden. Anästhesist. 28:1979;299-305.
35. Ware, J.A., Salzman, E.W., 1989. Use of heparin in treatment of thromboembolic disorders. In: Heparin, chemical and biological properties, clinical applications, vol. Lane, D.A., Lindahl, U. (Eds.). Edward Arnold, London.
36. Warlow C. Venous thromboembolism after stroke. American Heart Journal. 96:1978;283-290.
37. Yun J.H., Ma S.-C., Fu B., Yang V., Meyerhoff M. Direct potentiometric membrane electrode measurements of heparin binding to macromolecules. Electroanalysis. 5:1993;719-724.